hexamethonium has been researched along with Adiadochokinesis in 2 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, AD | 2 |
| Dar, MS | 2 |
2 other studies available for hexamethonium and Adiadochokinesis
| Article | Year |
|---|---|
Mouse cerebellar nicotinic-cholinergic receptor modulation of Delta9-THC ataxia: role of the alpha4beta2 subtype.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Cannabinoid Receptor Agonists; Cerebellar Ataxia; | 2006 |
Behavioral cross-tolerance between repeated intracerebellar nicotine and acute Delta(9)-tetrahydrocannabinol-induced cerebellar ataxia: role of cerebellar nitric oxide.
Topics: Animals; Cerebellar Ataxia; Cerebellum; Dihydro-beta-Erythroidine; Dronabinol; Drug Tolerance; Hexam | 2007 |